MedTrace Logo

Immune Metabolic Associations in Psoriatic Arthritis

NCT03399708 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2019-11-25

No results posted yet for this study

Summary

To use apremilast in clinical practice as a molecular probe to evaluate the effects of PDE4 inhibition on the cardiometabolic status and immune profile in patients with PsA and psoriasis.

Conditions

Interventions

DRUG

Apremilast 30mg

Apremilast will used in line with its license. This includes the standard dose titration scheme (see section 6) and then the usual maintenance dose of 30 mg twice daily orally.

Sponsors & Collaborators

  • NHS Greater Glasgow and Clyde

    lead OTHER

Principal Investigators

  • Stefan Siebert, MBChB PhD · Glasgow University and NHS GGC

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-12
Primary Completion
2019-10-12
Completion
2019-10-25

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03399708 on ClinicalTrials.gov